Galafold Approved in EU for Children 12 and Older With Fabry

Galafold Approved in EU for Children 12 and Older With Fabry

302097

Galafold Approved in EU for Children 12 and Older With Fabry

The European Commission has expanded the use of Galafold (migalastat) to children starting at age 12 and weighing at least 45 kilograms (99 pounds), with confirmed Fabry disease and a genetic mutation known to be sensitive to treatment. Galafold, developed by Amicus Therapeutics, is approved in over 40 countries. The treatment was first approved in the European Union for these Fabry patients, ages 16 and older, in 2016. In the U.S., the treatment is used in adults…

You must be logged in to read/download the full post.